OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
539858

Mediera Corp

Electrical Components & EquipmentVerified

Mediera Corp maintains a strong liquidity position, with a current ratio of 4.36 and cash and equivalents of 59,569,000 TWD, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow of 27,990,000 TWD further supports its liquidity and financial flexibility. Profitability metrics show a return on equity (ROE) of 3.27% and a return on assets (ROA) of 2.89%, which are below the industry median for Electrical Components & Equipment. The company's operating income of 9,829,000 TWD and net income of 17,357,000 TWD reflect modest profitability, with gross profit of 85,251,000 TWD indicating a relatively healthy margin in its core operations. The company's revenue is concentrated in the Taiwan market, with no disclosed international operations. This geographic concentration may expose the company to local economic and regulatory risks. The business is segmented into prescription drugs, indicated drugs, medical equipment, and food and health products, with no detailed revenue breakdown provided for each segment. Looking ahead, the company's revenue is expected to grow, with the latest actual revenue reported at 279,327,000 TWD. However, the growth trajectory is not explicitly quantified in the outlook. Capital expenditures are minimal, with a negative value of -1,733,000 TWD, suggesting a focus on maintaining rather than expanding operations. Risk factors for Mediera Corp are assessed as low in terms of liquidity and dilution. There are no immediate filing-based liquidity or dilution flags detected. The company's low debt levels and strong cash reserves reduce financial risk. Additionally, the absence of dilution potential and no recent equity issuance suggests a stable capital structure. Recent events include the latest actual EPS of 0.08 TWD and revenue of 279,327,000 TWD, as reported by analysts. No significant filings or transcripts have been disclosed that would indicate major operational or strategic changes in the near term.

30-day price · 5398-4.00 (-16.7%)
Low$19.65High$24.60Close$19.90As of15 May, 00:00 UTC
Profile
CompanyMediera Corp
Ticker5398.TWO
SectorIndustrials
BusinessIndustrial Goods
Industry groupIndustrial Goods
IndustryElectrical Components & Equipment
AI analysis

Business. Mediera Corp is a Taiwan-based company primarily engaged in medical biotechnology, producing prescription drugs, indicated drugs, medical equipment, and food and health products, while also offering health screening services, mainly operating in the Taiwan market.

Classification. Mediera Corp is classified under the Industrials economic sector, Industrial Goods business sector, and Electrical Components & Equipment industry, with a classification confidence of 0.92.

Mediera Corp maintains a strong liquidity position, with a current ratio of 4.36 and cash and equivalents of 59,569,000 TWD, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow of 27,990,000 TWD further supports its liquidity and financial flexibility. Profitability metrics show a return on equity (ROE) of 3.27% and a return on assets (ROA) of 2.89%, which are below the industry median for Electrical Components & Equipment. The company's operating income of 9,829,000 TWD and net income of 17,357,000 TWD reflect modest profitability, with gross profit of 85,251,000 TWD indicating a relatively healthy margin in its core operations. The company's revenue is concentrated in the Taiwan market, with no disclosed international operations. This geographic concentration may expose the company to local economic and regulatory risks. The business is segmented into prescription drugs, indicated drugs, medical equipment, and food and health products, with no detailed revenue breakdown provided for each segment. Looking ahead, the company's revenue is expected to grow, with the latest actual revenue reported at 279,327,000 TWD. However, the growth trajectory is not explicitly quantified in the outlook. Capital expenditures are minimal, with a negative value of -1,733,000 TWD, suggesting a focus on maintaining rather than expanding operations. Risk factors for Mediera Corp are assessed as low in terms of liquidity and dilution. There are no immediate filing-based liquidity or dilution flags detected. The company's low debt levels and strong cash reserves reduce financial risk. Additionally, the absence of dilution potential and no recent equity issuance suggests a stable capital structure. Recent events include the latest actual EPS of 0.08 TWD and revenue of 279,327,000 TWD, as reported by analysts. No significant filings or transcripts have been disclosed that would indicate major operational or strategic changes in the near term.
Key takeaways
  • Mediera Corp has a strong liquidity position with a current ratio of 4.36 and significant cash reserves.
  • The company's profitability is modest, with ROE and ROA below industry medians.
  • Revenue is concentrated in the Taiwan market, which may limit diversification and increase local risk exposure.
  • The company maintains a conservative capital structure with minimal debt and no immediate dilution risks.
  • Growth in revenue is expected, but the pace and drivers are not clearly defined in the available data.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$229.8M
Gross profit$85.3M
Operating income$9.8M
Net income$17.4M
R&D
SG&A
D&A
SBC
Operating cash flow$9.1M
CapEx-$1.7M
Free cash flow$28.0M
Total assets$600.8M
Total liabilities$70.2M
Total equity$530.6M
Cash & equivalents$59.6M
Long-term debt$12.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$530.6M
Net cash$47.0M
Current ratio4.4
Debt/Equity0.0
ROA2.9%
ROE3.3%
Cash conversion53.0%
CapEx/Revenue-0.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Industrial Goods · cohort 13 companies
Metric5398Activity
Op margin4.3%9.4% medp25 9.4% · p75 9.4%bottom quartile
Net margin7.6%5.8% medp25 5.8% · p75 5.8%top quartile
Gross margin37.1%26.9% medp25 26.9% · p75 26.9%top quartile
R&D / revenue2.0% medp25 1.6% · p75 3.0%
CapEx / revenue-0.8%2.4% medp25 1.6% · p75 3.3%bottom quartile
Debt / equity2.0%106.4% medp25 106.4% · p75 106.4%bottom quartile
Observations
IR observations
Last actual EPS0.08 TWD
Last actual revenue279,327,000 TWD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 15:29 UTC#bd3a4d2b
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 14:12 UTCJob: 95e828fb